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Introduction
Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome are prone to the development of brain (glial cell) tumors that arise in young children along the optic pathway (optic pathway glioma; OPG) (1, 2) . NF1-associated OPGs are World Health Organization grade I astrocytomas composed of glial fibrillary acidic protein (GFAP)-immunoreactive cells (3) .
These tumors have low proliferative indices and commonly exhibit indolent clinical behavior.
While many of these tumors do not require treatment, those that lead to reduced visual function are managed with carboplatin/vincristine chemotherapy. However, genotoxic therapies are concerning in the setting of a tumor predisposition syndrome. For this reason, numerous studies have focused on the identification of targeted therapies for these common tumors in children with NF1 (4, 5) .
To develop preclinical small-animal models of NF1-associated optic glioma, we and others have employed genetically-engineered Nf1 mutant mice (6, 7) . Nf1+/-mice with Nf1 gene inactivation in GFAP+ cells develop optic gliomas in the prechiasmatic optic nerve and chiasm by 3 months of age (8, 9) . Similar to their human counterparts, these Nf1 mouse gliomas have low proliferative indices, and exhibit microglial infiltration and increased vascularity (9, 10) .
Based on their similarity to NF1-associated optic glioma, Nf1 GEM have been successfully employed for proof-of-principle preclinical studies using conventionally-used chemotherapy (temozolomide) to demonstrate tumor shrinkage, reduced glioma proliferation, and increased tumor apoptosis (11) .
Analysis of Nf1-deficient astrocytes as well as other NF1-deficient cell types previously revealed that the NF1 protein, neurofibromin, functions to negatively regulate cell growth by inactivating the Ras proto-oncogene (12, 13) . Neurofibromin contains a 300 amino acid residue domain with sequence similarity to members of the GTPase activating protein (GAP) family of molecules that serve to accelerate the conversion of Ras from its active GTP-bound to its inactive GDP-bound form (14) (15) (16) . Subsequent studies further showed that neurofibromin Ras- Banerjee, et al., page 4 mediated growth regulation operates through the mammalian target of rapamycin (mTOR) pathway (17, 18) . In this regard, NF1-deficient human and mouse cells exhibit increased mTOR pathway activation as evidenced by high levels of activity of the mTOR effector, ribosomal S6.
Using activation-specific S6 phospho-antibodies, several groups showed increased mTOR activation in human and mouse NF1-associated tumors, including human and mouse optic gliomas. This exciting finding prompted investigators to perform preclinical studies using the rapamycin macrolide to inhibit mTOR activation and NF1-deficient tumor growth in vivo (11, 17, 19) . In these studies, we previously showed that Nf1 mouse optic glioma proliferation was reduced following rapamycin treatment. Treatment with 5 mg/kg/day rapamycin for 14 days resulted in reduced tumor proliferation using Ki67 (MIB-1) immunohistochemistry and attenuated mTOR pathway activation by phospho-S6 immunostaining; however, this effect was dependent on the continued presence of rapamycin, such that proliferation and mTOR activity returned to pre-treatment levels 2 weeks after the cessation of rapamycin treatment. In contrast, Nf1 mutant mice treated with 20 mg/kg/day rapamycin had a durable response that was not dependent on continued drug dosing (11) . These interesting results prompted us to define the molecular basis for this treatment effect.
In the current study, we measured rapamycin levels in the blood and brain in Nf1 mutant mice following treatment with 0, 2, 5 and 20 mg/kg/day rapamycin, and correlated drug dose with mTOR pathway signaling and proliferation in vivo. We found that 5 mg/kg/day rapamycin dosing resulted in increased AKT activation, which was suppressed following 20 mg/kg/day rapamycin treatment. However, neither Ki67 nor phospho-S6 activity were robust biomarkers for the in vivo response to rapamycin. Instead, phospho-histone-H3 most strongly correlated with combined inhibition of both S6 and AKT phosphorylation. We recapitulated these in vivo results using Nf1-deficient mouse low-grade glioma cells in vitro to demonstrate that combined treatment with rapamycin and the LY294002 PI3-Kinase inhibitor suppressed cell growth to levels seen with higher doses of rapamycin alone. Collectively, these data suggest that Banerjee, et al., page 5 additional biomarkers will be required to adequately assess mTOR target inhibition and tumor proliferative responses to rapamycin treatment in vivo.
Materials and Methods
Mice. Five-six week-old Nf1 ; GFAP-Cre) were used. These mice lack Nf1 gene expression in GFAP+ (glial) cells, and were generated by successive intercrossing of
Nf1
flox/flox and Nf1 flox/wt ; GFAP-Cre mice as previously described (6) . All mice were used in accordance with established and approved animal studies protocols at the Washington Banerjee, et al., page 6 and analyzed using a modification of an online extraction liquid chromatography-electrospray ionization-tandem mass spectrometry (LC/LC-MS/MS) assay previously described for the analysis of zotarolimus in blood and tissues (20 HPLC grade water / HPLC grade methanol containing the internal standard sirolimus-d3 (5 ng/mL) was added. Samples were vortexed for 2.5 minutes at room temperature and centrifuged at 13,000·g for 8 minutes at 4°C using a bench-top microfuge. The supernatant was transferred into 2 mL HPLC autosampler glass vials and 100 μL was injected into the LC/LC-MS/MS system (HPLC Agilent 1100 Series, Applied Biosystems/Sciex API 4000). HPLC I was used for on-line sample extraction, HPLC II for sample analysis and both were connected via a 6-port switching valve (20) .
For on-line sample clean-up, an extraction column (4.6 x 12.5 mm, 5µm, Eclipse XDB-C8, Agilent) was used and samples were washed using 20% HPLC grade methanol / 80% HPLC grade water + 0.1% formic acid delivered at a flow rate of 5mL/min for 1min. The analytes were then back-flushed onto a C8 analytical column (4.6 x 150 mm, 5µm, Zorbax XDB -C8, Agilent) that was kept at 65°C. The following gradient was run: 87% methanol/ 13% 0.1% formic acid to 100% methanol within 2.0 min and then 100% methanol for an additional 1.5 min. The flow rate was 1mL/min. The mass spectrometer was run in the positive MRM (multiple reaction monitoring) mode. The de-solvation gas was heated to 600°C, the declustering potential (DP) was set to 160 V and the collision energy (CE) to 77eV. The following ion transitions were Statistical analysis. The measures of all biomarkers were summarized using the mean and standard error of mean (SEM). The raw data were checked graphically and data transformation was performed as necessary. The relationship between blood and brain rapamycin concentrations was described by linear regression analysis. For each biomarker, the differences of means among rapamycin dose levels were compared using 1-way ANOVA, followed by posthoc tests to compare individual treatment conditions to the wild-type or untreated group. To control the family-wise false-positive rate at the designed 0.05 level, however, such post-hoc comparisons were conducted only if the overall difference in ANOVA was significant. All the analyses were implemented by the comprehensive statistical package R (http://cran.rproject.org/) and p values less than 0.05 were considered to be statistically significant. Banerjee, et al., page 9
Results
Brain rapamycin levels are exponentially correlated with blood rapamycin levels. One of the major obstacles in translating preclinical drug studies to human clinical trials is a relative paucity of reported blood and target tissue drug levels. In these studies, we sought to determine whether rapamycin crosses the blood-brain barrier and how brain tissue levels correlated with rapamycin dose and circulating levels. First, we measured rapamycin concentrations in the blood and brain tissue of 6-8 week-old Nf1 (Fig. 1A ) and brain tissue (Fig. 1B) .
These observations demonstrated that intraperitoneal rapamycin administration increases both blood and brain levels. However, brain rapamycin levels were exponentially correlated with blood rapamycin levels ( Second, to additionally evaluate mTOR activity in the brain after rapamycin treatment, we examined Thr 37/46 phosphorylation of the mTOR effector 4EBP1 (Fig. 2B) . Similar to S6 activation, 4EBP1 phosphorylation was unchanged at the 2mg/kg/day dose, whereas significant reductions were observed both at 5 and 20mg/kg/day rapamycin doses. Third, recent studies demonstrated that mTOR regulates Jagged-1 levels in tuberous sclerosis complex (TSC)-deficient cells (28) . To determine whether Jagged-1 levels are elevated in Nf1-deficient primary astrocytes, we performed Western blotting. We observed a 2-fold increase in Jagged-1 protein expression in Nf1-/-relative to wild-type astrocytes (Supplementary Fig. S2A ). This increase in Jagged-1 protein expression was inhibited by rapamycin treatment; however, Jagged-1 levels were reduced in Nf1 GFAP CKO mice treated with 2mg/kg/day rapamycin -a dose where no change in phospho-S6 expression was seen (Supplementary Fig. S2B ).
While neurofibromin regulates cell growth through the mTOR pathway in many distinct cell types, we previously demonstrated that increased Nf1-deficient astrocyte growth reflects raptordependent signaling through the Rac1/STAT3 pathway (21) . In light of this tissue specificity, we next measured STAT3 activation using phospho-STAT3 (Ser 727 ) antibodies. Consistent with the results obtained using phospho-S6 and phospho-4EBP1, STAT3 inhibition was only observed in the brain at the 5 and 20 mg/kg/day doses (Fig. 2C) . Collectively, these data demonstrate that inhibition of mTOR downstream signaling in the brain requires at least 5mg/kg/day rapamycin treatment.
Ki67 does not accurately reflect rapamycin inhibition of glial cell proliferation in vivo.
Previous preclinical studies from our laboratory and others have employed Ki67 as a marker of (11, 29) . In these studies, we found that either the number of Ki67 cells or the percent of Ki67-positive cells in Nf1+/-GFAP CKO mouse optic glioma tumors or Nf1-deficient glial cells correlated well with other markers of cell proliferation in vivo, including BrdU incorporation (11) . To determine whether Ki67 accurately reflected rapamycin inhibition of Nf1-deficient brain glial cell proliferation in vivo, we quantified the number of proliferating cells in a defined region of the dentate gyrus using standard Ki67 (MIB-1) immunostaining. Surprisingly, we observed a significant decrease in the number of Ki67-immunoreactive (proliferating) cells (Fig. 3A) at 2mg/kg/day rapamycin. As shown above, 2mg/kg/day rapamycin did not inhibit mTOR signaling. This finding suggests that Ki67 may not be the ideal marker to measure glial cell proliferation in preclinical Nf1 GEM low-grade glioma rapamycin drug studies. Using a less conventional marker of cell proliferation (PCNA), statistically significant reductions in cell proliferation were only observed following 20 mg/kg/day rapamycin treatment (Supplementary   Fig. S3B ). However, the low numbers of PCNA-immunoreactive cells present in each section limits the routine use of this marker for preclinical studies, consistent with other reports comparing these two biomarkers (30) (31) (32) (33) .
To identify more accurate markers of Nf1-deficient glial cell proliferation in vivo, we next measured cyclin D1 levels. Cyclin D1 was chosen, based on our previous studies which demonstrated that STAT3 regulates cyclin D1 expression in Nf1-deficient cells (21) .
Interestingly, we found that inhibition of cyclin D1 was only observed at 20mg/kg/day rapamycin dosing (Fig. 3B) . To confirm the apparent inhibition of cell growth only at 20mg/kg/day rapamycin dosing, we measured phospho-histone H3 (HH3) levels using phospho-HH3 (Ser   10   ) antibodies. Similar to the results obtained using cyclin D1 antibodies; we observed reduced phospho-HH3 only with 20mg/kg/day rapamycin (Fig. 3C) . Collectively, these results demonstrate that phospho-HH3 and cyclin D1 may be more accurate indicators of mTORmediated glial growth inhibition in the brain. The inability of 5mg/kg/day rapamycin to strongly inhibit glial proliferation in vivo reflects AKT hyperactivation. Based on the results described above, we sought to determine why equivalent mTOR pathway inhibition using several surrogate markers of mTOR activity was observed following 5 and 20mg/kg/day rapamycin treatment; however, only 20mg/kg/day rapamycin led to reduced glial cell proliferation in vivo. Previous studies have demonstrated that rapamycin inhibition can paradoxically cause an increase AKT activation as a result of inhibition of TORC1-mediated AKT inhibition and/or TORC2-mediated AKT activation (34) (35) (36) (37) . While this anomalous AKT activation has been reported in human NF1-associated tumors (19, 29) , this has not been previously observed in Nf1 GEM tumors or primary tissues (11, 38) . To determine whether AKT activation was seen in the brain following rapamycin treatment, we measured AKT Ser 473 phosphorylation in vivo, and found a 4-fold increase in AKT activation at 5mg/kg/day, but not at 2 or 20mg/kg/day. These results suggest that AKT activation might counteract the growth suppressive effects of rapamycin-mediated mTOR inhibition.
To establish an in vitro model for these observations, we examined AKT activation, mTOR activity and cell proliferation in Nf1-deficient K4622 glioma cells treated over a wide range of rapamycin concentrations from 0.001nM to 500 nM (data not shown). Based on this dose range, we selected three rapamycin doses (0.001nM, 0.75nM and 10nM) to parallel the effects of 2, 5, and 20 mg/kg/day rapamycin treatment. Similar to the results obtained following 5mg/kg/day rapamycin treatment in vivo, we found that 0.75nM rapamycin resulted in a 5-fold increase in AKT activation compared to vehicle control, whereas no change in AKT Ser 473 phosphorylation was observed at 0.001nM or 10nM rapamycin (Fig. 4A) . No change in AKT phosphorylation at residue Thr-308 was observed following 0.75 nM rapamycin treatment (Supplementary Fig.   S4A ), and no increased in AKT Thr-308 phosphorylation was found in Nf1-deficient astrocytes relative to their wild-type controls (data not shown). In addition, S6-Ser 235/236 , STAT3-Ser
727
, and 4EBP1-Thr 37/46 phosphorylation was decreased in a rapamycin dose-dependent fashion (Fig. 4B) . observed a maximum inhibitory effect on cell growth and histone-H3 phosphorylation following 10nM rapamycin treatment (Fig. 4C-D) , with no further inhibition observed at 100 or 500 nM doses (Supplementary Fig. S5 ). Collectively, these results suggest that effective brain glial cell growth inhibition by rapamycin requires doses that inhibit both TORC1 (S6; 4EBP1, and STAT3) and TORC2 (AKT) downstream pathways.
Maximal Nf1-deficient glial cell growth inhibition requires both mTOR and AKT silencing.
Since maximal glial growth inhibition was only observed when both raptor-mediated (S6, 4EBP1, STAT3) and rictor-mediated (AKT) mTOR downstream pathways were silenced by rapamycin treatment, we next sought to determine whether combined rapamycin and AKT inhibition could suppress Nf1-/-glioma cell growth similar to "high dose" (10nM) rapamycin treatment. In these experiments, we examined the effect of combined mTOR (rapamycin) and (Fig. 5A ) was significantly attenuated, and cell proliferation (Fig. 5B) was reduced by ~36%. Whereas pharmacological inhibition of PI3-K (30 μM) reduced K4622 glioma cell growth by 50%, combined 0.750nM rapamycin and 30 μM LY294002 treatment resulted in an 81% reduction in cell proliferation (Fig. 5B) , similar to what was obtained following 10nM rapamycin treatment.
This reduction in cell growth was not the result of increased apoptosis, as assessed by cleaved PARP immunoblotting (Supplementary Fig. S4 ). Banerjee, et al., page 14
Next, we employed the NVP-BEZ235 dual kinase inhibitor to target both PI3K and mTOR (39, 40) . Consistent with the results obtained following combined LY294002 and rapamycin treatment, AKT and mTOR (S6, STAT3 and 4EBP1) phosphorylation were blocked by NVP-BEZ235 at all doses examined (Fig. 6A) . As above, AKT phosphorylation on residue Ser-473, but not Thr-308, was inhibited by NVP-BEZ235 treatment. The observed suppression of AKT and mTOR activities resulted in inhibition of Nf1-deficient K4622 glioma cell growth (Fig. 6B) .
Collectively, these results demonstrate that combined PI3K and mTOR blockade effectively inhibits Nf1-deficient glioma proliferation
Discussion
Preclinical cancer studies are designed to provide instructive information that informs human clinical trials. These small-animal drug trials aim to assess drug efficacy in the intact animal, correlate target inhibition with tumor growth suppression, and/or validate surrogate biomarkers of treatment success. The ability to achieve these objectives is highly dependent on the availability of accurate models that duplicate key features of the human condition coupled with a rigorous evaluation of potential drug therapies. In the case of NF1-associated tumors, including optic glioma and malignant peripheral nerve sheath tumor (MPNST), rapamycin inhibits tumor growth in vivo (11, 19, 29, 38) . However, in these various models, there were significant differences in the dose of rapamycin employed (1mg/kg/day to 20mg/kg/day) and the effects of rapamycin on mTOR signaling. This variation could reflect differences in tumor species of origin (mouse; (11, 38) versus human (19, 29) ), host species immunocompetence (geneticallyengineered mice (11, 38) versus tumor explants into immunocompromised mice (19, 29) ), or tumor location (brain (11, 38) versus body (19, 29, 38) ). Similarly, these differences could result from disparities in rapamycin bioavailability. In the current report, we performed a series of experiments to address some of these critical issues. 
First, we sought to define the relationship between blood and brain rapamycin levels and drug dose. While we observed a dose-dependent increase in both blood and brain rapamycin concentrations with escalating rapamycin doses, the relationship between blood and brain rapamycin levels deserves further discussion. Most Nf1 mouse preclinical studies have employed rapamycin doses between 1 and 10 mg/kg/day (11, 38) . In the brain, there was a linear relationship between blood and brain rapamycin concentrations at the lower doses (2 and 5 mg/kg/day); however, we observed an exponential relationship at the higher dose (20mg/kg/day). This result suggests that rapamycin brain delivery may involve different order kinetics than that observed for peripheral tissues. It is well established that p-glycoprotein as an efflux transporter is a critical component of the blood-brain barrier (41) . As such, it limits the entry of drugs that are substrates, like rapamycin, into the brain (42) . Our data may indicate that at the highest rapamycin dose (20 mg/kg) systemic rapamycin exposure exceeds the capacity of brain barrier efflux transporters, leading to the observed exponential increase in brain rapamycin concentrations.
Next, we evaluated mTOR target inhibition in the brain following rapamycin treatment, and were surprised to find that phospho-S6 inhibition did not correlate with reduced Nf1-deficient glial cell proliferation. This is consistent with in vitro studies using Nf1-deficient NPCis glioma cells or primary brain astrocytes (Supplementary Fig. S6A-B) . In these experiments, >90% reduction in phospho-S6 levels (using either phospho-Ser 235/236 or phospho-S6-Ser 240/244 antibodies) was seen at rapamycin doses 10-fold lower than doses required to inhibit Nf1-deficient glial cell proliferation. Similarly, other mTOR downstream effectors, including STAT3
and 4EBP1, showed similar relationships between target inhibition and growth suppression.
These findings suggest that maximal rapamycin-mediated growth suppression involves more than mTOR/raptor downstream target inhibition.
It is also possible that the inability of mTOR/raptor inhibition (phospho-S6/4EBP1/STAT3 levels) to predict mTOR-mediated growth suppression reflects rapamycin-induced mTOR- NPCis glioma cell growth inhibition is similar to that observed with high-dose rapamycin treatment alone. While these findings indicate that maximal growth suppression requires silencing of both mTOR and AKT activation, the combined use of phospho-AKT and phospho-S6 as surrogate biomarkers would be misleading. It would be impossible to determine whether low phospho-AKT and phospho-S6 levels in the tumor reflect inadequate target inhibition (2mg/kg/day) or the desired effect (20mg/kg/day). In this regard, there is a pressing need for more accurate biomarkers that better demonstrate optimal mTOR pathway inhibition following rapamycin treatment.
Previous rapamycin-based Nf1 preclinical mouse model drug studies have measured tumor volume, and observed that tumor size reduction was completely dependent on continuous drug treatment. In the Nf1 GEM optic glioma model, we found that cessation of 5mg/kg/day rapamycin therapy resulted in increased tumor proliferation (as assessed by Ki67 immunohistochemistry) and increased tumor volume within 2 weeks. Similar findings were reported in NF1-associated MPNST preclinical studies, supporting the conclusion that these doses of rapamycin do not achieve a durable effect. One exception to this short-lived antitumoral response was seen following 20mg/kg/day rapamycin in Nf1 GEM optic glioma (11) .
For this reason, we sought to identify proliferation biomarkers that correlate with the sustained tumor growth suppression. In the current study, we found that phospho-histone-H3 and cyclin D1 more accurately reflected reduced Nf1-deficient glial cell growth in response to rapamycin in vitro and in vivo. The finding that cyclin D1 levels paralleled growth inhibition has also been noted in NF1-deficient MPNST preclinical studies (38) GTPase activating domain (GRD) of neurofibromin was sufficient to restore cyclin D1 levels to normal.
As we attempt to leverage the emerging experience with GEM preclinical therapeutic studies to design more effective drug regimens for brain tumors, it becomes increasingly important to validate surrogate markers of disease activity and target inhibition in relevant smallanimal models. The findings described in this study suggest that blood rapamycin levels do not 
